CD166 as a Stem Cell Marker? A Potential Target for Therapy Colorectal Cancer?

Colorectal cancer (CRC) is the third most common cancer in men and the second in women worldwide, accounting for almost 10 % of all cases [1,2]. The USA and Europe have high rates compared to Africa and Asia [3,4]. Only in the United States, nearly 135,000 new cases diagnosed annually that about 50,000 people will die of the disease [5]. In Iran CRC is the third most common cancer in women and the Fifth in men [6]. Two big problem is the high ability of CRC to form secondary tumours, particularly in the lung and liver and the high heterogeneity of the genetic and epigenetic changes among the individual tumours. Continual development of CRC is described on the Figure 1 [7].